Early Birds: FSD Pharma Inc. (NASDAQ: HUGE) Taking Center Stage on Approximate 95% Move in the Pre-Market

This Next Profile Has Us Very Excited and You'll Soon See Why…

Market Crux Announces New Profile! Immediately Turn Your Attention to FSD Pharma Inc. (NASDAQ: HUGE)! FSD Pharma Inc. (NASDAQ: HUGE) Comes Stacked with Several  Potential Catalysts Including: Innovative Solutions: Developing Treatments For Neurodegenerative, Metabolic, And Al-co-hol Misuse Disorders! World-Class Pipeline: Targeting Multi-Bln Dollar Markets With  Decades Of Research! Diversified Portfolio: First Product Launch In 2024, Tackling  Various Disorders! Elite Team: Scientists With Extensive Expertise In Therapeutics Discovery! Strong Intellectual Property: Robust IP Portfolio Ensuring  Competitive Edge! Recent Developments: Clinical Trial Protocols For Unbuzzd™ And  Lucid-MS Submitted! Current Market Position: Company Recovering From A 52-Week Low  With Analyst Target Suggesting Significant Growth Potential! Do Not Miss Out on FSD Pharma Inc. (NASDAQ: HUGE)! August 9, 2024 Dear Reader, After the streak that we’ve been on, with recent profiles totaling 765% in approximate moves, all eyes need to be on FSD Pharma Inc. (NASDAQ: HUGE). And it looks like FSD Pharma Inc. (NASDAQ: HUGE) is keeping the streak going, taking center stage early on an approximate 95% move in the pre-market. But you’ll need to hurry because after (HUGE) just came off a new 52-week low today at $.072, as shares reversed the trend, moved up approx. 31%, reaching $.0945, triggering 14 Bullish Signals on Trading View’s technical analysis tool using the 15 minute time-frame as of this writing. With a 52-week high of $1.6799 and a $4.60 analyst target, FSD Pharma Inc. (NASDAQ: HUGE) is one company that needs to be at the top of your watchlist starting right now. You see, FSD Pharma Inc. (NASDAQ: HUGE) is at the forefront of biopharmaceutical research, focusing on developing innovative assets and solutions for treating challenging neurodegenerative, metabolic, and al-co-hol misuse disorders.  With dr-ug candidates in various stages of development, FSD Pharma Inc. (NASDAQ: HUGE) is dedicated to making a significant impact in these critical areas of healthcare. Highlights of  FSD Pharma Inc. (NASDAQ: HUGE) World-Class Pipeline: FSD Pharma Inc. (NASDAQ: HUGE) boasts a world-class pipeline targeting multi-billion dollar markets. Their research addresses unmet medical needs, backed by decades of dedicated research and development. Diversified Product Portfolio: The company has a diversified product portfolio, with its first product launch in 2024. This diversity positions FSD Pharma to tackle a range of disorders with novel therapeutic solutions. Massive Market Potential: With a recently added seasoned management team, FSD Pharma Inc. (NASDAQ: HUGE) is well-equipped to navigate and capitalize on its massive market opp. Elite Team: The company's elite team of scientists brings extensive expertise in therapeutics discovery and pharmaceutical development, driving forward their innovative pipeline. Strong Intellectual Property: FSD Pharma Inc. (NASDAQ: HUGE)’s robust intellectual property portfolio underpins its competitive edge and secures its pioneering advancements in the biopharmaceutical sector. Current Market Position: As of 8/08/2024, FSD Pharma is coming off its 52-week low of $0.072, with a 52-week high of $1.6799 and an analyst target of $4.60, indicating significant growth potential. Recent Developments Submission of Clinical Trial Protocol for Unbuzzd™ in Acute  Al-co-hol Intoxication FSD Pharma Inc. (NASDAQ: HUGE) has recently submitted a clinical trial protocol to study the safety and efficacy of Unbuzzd™ in acute al-coh-ol intoxication.  This trial, named METAL-2, will involve healthy volunteers and aims to evaluate the effectiveness of Unbuzzd™ in alleviating the effects of acute a-lco-hol intoxication.  The protocol has been submitted to the institutional review board (IRB) in the USA, and recruitment will commence upon IRB approval. Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at FSD Pharma, expressed excitement over this milestone, marking a significant step towards clinical validation of Unbuzzd™. Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-MS In May, FSD Pharma Inc. (NASDAQ: HUGE) announced the submission of a Phase-1 multiple ascending doses (MAD) clinical trial application for Lucid-21-302 (Lucid-MS) to an ethics committee in Australia.  This trial, titled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants," aims to assess the safety and pharmacokinetics of Lucid-MS in healthy adults.  The submission to the human ethics review committee (HREC) is a critical step towards initiating the MAD trial, following the successful completion of a Phase-1 single ascending dose (SAD) trial. Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound designed to treat multiple sclerosis (MS).  This patented new chemical entity has shown promise in preclinical models by preventing demyelination, the underlying cause of MS and other neurodegenerative diseases.  The prior SAD study demonstrated that Lucid-MS is safe and well-tolerated at doses ranging from 50-300 mg, with consistent pharmacokinetics between fed and fasted states. Here’s 7 reasons to immediately start your research on  FSD Pharma Inc. (NASDAQ: HUGE)... 1. Innovative Solutions: FSD Pharma Inc. (NASDAQ: HUGE) is dedicated to developing groundbreaking treatments for challenging neurodegenerative, metabolic, and al-co-hol misuse disorders. 2. World-Class Pipeline: The company boasts a robust pipeline targeting multi-bln dollar markets, addressing unmet medical needs with decades of research backing their efforts. 3. Diversified Portfolio: With a diversified product portfolio and the first product launch in 2024, FSD Pharma Inc. (NASDAQ: HUGE) is well-positioned to tackle a range of disorders with novel therapeutic solutions. 4. Elite Team: FSD Pharma Inc. (NASDAQ: HUGE)’s team of scientists brings extensive expertise in therapeutics discovery and pharmaceutical development, driving forward their innovative pipeline. 5. Strong Intellectual Property: The company's strong intellectual property portfolio underpins its competitive edge and secures its pioneering advancements in the biopharmaceutical sector. 6. Recent Developments: The submission of clinical trial protocols for Unbuzzd™ and Lucid-MS highlights FSD Pharma Inc. (NASDAQ: HUGE)’s commitment to advancing its pipeline and bringing new therapeutic solutions to market. 7. Current Market Position: With shares coming off a 52-week low of $.072 today and an analyst target of $4.60, FSD Pharma Inc. (NASDAQ: HUGE) shows significant growth potential and strategic advancements in the biopharmaceutical industry. FSD Pharma Inc. (NASDAQ: HUGE) is at the forefront of developing groundbreaking treatments for neurodegenerative, metabolic, and al-co-hol misuse disorders. Their world-class pipeline targets multi-billion dollar markets, addressing critical unmet medical needs with decades of research support.  With a diversified product portfolio and the first product launch set for 2024, FSD Pharma Inc. (NASDAQ: HUGE) is poised to tackle a range of disorders with novel therapeutic solutions. The company boasts an elite team of scientists and a strong intellectual property portfolio, securing its pioneering advancements in the biopharmaceutical sector. Recent clinical trial protocol submissions further demonstrate FSD Pharma Inc. (NASDAQ: HUGE)’s dedication to advancing their innovative pipeline. With shares coming off a 52-week low of $.072 earlier today and an analyst target of $4.60, FSD Pharma Inc. (NASDAQ: HUGE) shows significant growth potential.  Make sure (HUGE) is at the very top of your watchlist this morning. I’m serious! Pull up FSD Pharma Inc. (NASDAQ: HUGE) and start your research now. FSD Pharma Inc. (NASDAQ: HUGE) is keeping the streak going, taking center stage early on an approximate 95% move in the pre-market. I’ll check back in with you shortly. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer  Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 08/08/2024 and ending on 08/09/2024 to publicly disseminate information about (HUGE:US) via digital communications. Headline Media LLC has been paid an additional seven thousand five hundred USD. To date Headline Media LLC has been paid twelve thousand five hundred USD and owns zero shares of (HUGE:US). Please see important disclosure information here: https://marketcrux.com/huge-disclosure-1321/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice